History
Documents created during the development process.
Assessment report sent for information
Background information
-
Insomnia - newer hypnotic drugs: review decision - August 2010 information
-
Appendix A: Decision paper considered by the Institute's Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 72 KB)
-
-
Appendix A: Provisional matrix of consultees and commentators
-
Appendix A: Provisional matrix of consultees and commentators (MSWord 69 KB)
-
Appendix B: Proposal paper presented to NICE's Guidance Executive
-
Appendix B: Proposal paper presented to NICE's Guidance Executive (PDF 109 KB)
-
TA77 Insomnia - newer hypnotic drugs: distribution list
-
TA77 Insomnia - newer hypnotic drugs: distribution list (PDF 56 KB)
-
-
-
Appendix 1
-
Actavis
-
-
British Sleep Society
-
-
Counsel and Care
-
-
Department of Health
-
-
Dowelhurst Ltd
-
-
NHS Quality Improvement Scotland
-
-
Pfizer Ltd
-
-
Royal College of Nursing
-
-
Rosemont Pharmaceuticals
-
-
Sandoz Ltd
-
-
Teva UK
-
-
Wyeth Pharmaceuticals
-
-
Appendix A - Matrix of consultees and commentators.
-
Appendix A - Matrix of consultees and commentators. (PDF 59 KB)
Final Appraisal Determination: Zaleplon, zolpidem and zopiclone for the short-term management of insomnia
-
Final Appraisal Determination: Zaleplon, zolpidem and zopiclone for the short-term management of insomnia
-
Appraisal Consultation Document: Zaleplon, zolpidem and zopiclone for the management of insomnia
Protocol: Newer hypnotic drugs for short-term pharmacotherapy for insomnia
-
Protocol: Newer hypnotic drugs for short-term pharmacotherapy for insomnia
-
Protocol: Newer hypnotic drugs for short-term pharmacotherapy for insomnia (PDF 201 KB)
Final Scope: Zaleplon, zolpidem and zopiclone for the management of short-term insomnia
-
Final Scope: Zaleplon, zolpidem and zopiclone for the management of short-term insomnia
-
Final Scope: Zaleplon, zolpidem and zopiclone for the management of short-term insomnia (PDF 70 KB)